Pacific Edge Reports Resilient Performance In FY25
30 May 2025
Pacific Edge today reports a resilient financial result for the year to the end of March 2025. Improvements in the performance of the sales force, operating efficiencies and cash collection gains over the financial year have positioned the company well as it works towards regaining Medicare coverage of its tests.
Pacific Edge today also announces a NZ$20 million equity raising to capitalize on recent clinical and commercial milestones, grow in non-Medicare channels and regain Medicare coverage. The details of the capital raising are covered in a separate announcement to the NZX and ASX today.
FY25 FINANCIAL PERFORMANCE2
Operating revenue down 8.6% on FY 24 to $21.8 million, reflecting Medicare uncertainty. Total revenue is down 16% on FY 24 to $24.6 million
Total laboratory throughput3 (TLT) of Cxbladder tests fell 11.5% on FY 24 to 28,894; commercial tests fell 9.9% on FY 24 to 26,42 tests
Tests/Sales FTE in the US for Q4 25 were reported at 405.6, up 6.4% on Q4 24; ASP4 for all commercial tests in the US increases to US$594 in FY 25 vs US$584 in FY 24 as operating efficiencies and cash collection gains continue to improve
Strong performance from the Southern California Permanente Medical Group, increased APAC volume and sustained sales force efficiencies reduce the impact of Medicare uncertainty and the reduced sales team reach
Net loss after tax +1.4% on FY 24 to $29.9 million, 2H 25 net loss +6.4% on 1H 25 led by increased expenditure on clinical research, Triage Plus commercialization and legal fees
Cash, cash equivalents and short-term deposits of $22.6 million at the end of FY25; cash burn of $13.4 million in 2H 25 down 6.7% on 1H 25
FY 25 STRATEGIC PERFORMANCE
Cxbladder Triage included in the American Urological Association (AUA) guidelines with a 'Grade A' evidence rating, the only biomarker to achieve this status
Triage Plus achieves a draft Medicare price of US$1,018.44, a significant premium to the current US$760 per test; full scale commercial launch is now contingent on re-coverage
Medicare coverage discontinued following Genetic Tests for Oncology (Specific Tests) (L39365) becoming effective after balance date (24 April 2025); Pacific Edge is now focused on regaining coverage for Triage and Monitor and obtaining coverage and launch of new products Triage Plus and Monitor Plus
Commercial team focused on profitable territories, non-Medicare revenue streams and selling the clinical and economic value of Cxbladder; Cxbladder Detect discontinued
FY25 Climate Disclosures released in compliance with NZCS
NOTE: PEB HAS RELEASED THIS UPDATE TO THE NZX AND ASX AS PER LISTING RULES [1]
1 PEB has released the information contained in this update to the NZX and ASX as it regards it to be material, as defined in the NZX Listing Rules and Section 231 of the FMC Act.
2 All comparisons are to the same period of the prior financial year unless otherwise stated.
3 Total Laboratory Throughput (TLT) includes commercial, pre-commercial and clinical studies testing.
4 ASP: US Average Sales Price (US Operating Revenue in USD / US Commercial Test Volumes)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NZ Herald
21 hours ago
- NZ Herald
Possible sale of Fletcher Construction end of a proud building era
The books are said to be a 'story of war and peace, of success and failure, and how New Zealand's premier builder coped in the face of many challenges'. Fletcher Construction may soon be sold and analysts suggest it could be worth up to $340 million. Photo / Getty Images Today's Fletcher Building is a shadow of the former Fletcher Challenge of the last century. And Fletcher Construction itself is a shadow of what the great company once was. Fletcher flagged the potential Fletcher Construction sale at its investor day on June 11 and again on July 22 in an NZX notice. Fletcher Construction is: Higgins, the civil construction company that Fletcher bought in 2016; Brian Perry Civil, bought by Fletcher in 1986; Fletcher Construction (major projects) division, part of the original 2001 float on the NZX. Fletcher Living, the company's home-building business, is not included in the sale. Fletcher Living doesn't come under Fletcher Construction. It is a separate division, headed by the accomplished, experienced Steve Evans, in that role for more than a decade. Andrew Reding heads Fletcher Building and is looking at divestment options for the Construction businesses. On the possible Fletcher Construction sale, CEO and MD Andrew Reding said in July: 'Given the quality and strong recent performance of our Construction businesses, and the role they will play in New Zealand's growing infrastructure pipeline, we were not surprised to receive inbound interest for them, which has motivated us to test whether there are attractive divestment options. 'No decision has been made to sell at this time, and we will carefully consider the value of any options presented from this process before deciding whether to move ahead.' The business says Fletcher Construction has 3700 staff working across the three brands. 'Since 1909, our people have planned, built, maintained and managed significant national infrastructure for the benefit of communities in New Zealand and the South Pacific. We have safety at our core and invest in innovation for the future,' Fletcher Construction said. In more recent years, Fletcher Construction had three jobs that caused problems: Auckland's new $1 billion-plus NZ International Convention Centre for SkyCity; Auckland waterfront's Commercial Bay for Precinct Properties; Justice & Emergency Precinct in Christchurch. In 2018, the Herald reported on 14 of 73 projects on its books that are loss-making or on watch. SkyCity Entertainment Group's NZ International Convention Centre has been a problem project for Fletcher Construction. Photo / Michael Craig Jobs had gone over the original bid cost and taken far longer than expected. Underbidding and lack of information flow to the board were two issues blamed then. The now former-CEO Ross Taylor said in 2018 that Fletcher Building would not be bidding for any further vertical construction work in New Zealand while it concentrated on completing existing projects. The company said at the time that the building and interiors market 'continues to be characterised by high contract risk and low margins', adding, 'we will no longer work in these conditions'. SkyCity is suing Fletcher Building and the Fletcher Construction Company for $330 million, saying it had taken 10 years instead of three to build the NZICC. The claim seeks damages for losses incurred by SkyCity arising from ongoing delays in the completion of the project, including those that resulted from the 2019 fire. In response, Fletcher said it had already flagged risks associated with the convention centre, it was committed to delivering the project and would vigorously defend itself. But SkyCity said the NZICC was now nearly six and a half years behind the contractually agreed delivery date of January 2019. Despite its problems, Forsyth Barr analysts have estimated Fletcher Construction could be worth $230m to $340m. More may be said about the sale at the company's annual results announcement on August 20. Anne Gibson has been the Herald's property editor for 25 years, written books and covered property extensively here and overseas.
Otago Daily Times
4 days ago
- Otago Daily Times
Synlait loss turnaround ‘will take time'
Canterbury-based milk processor Synlait Milk is anticipating a loss after tax of $27million to $40m after manufacturing challenges at its Dunsandel factory. The company announced to NZX the predicted result for the financial year ending July compared with a $182.1m loss the previous year. Synlait had to deal with manufacturing issues at its Dunsandel facility across a range of products, resulting in one-off costs. The company said the challenges had been resolved. The site is now in new-season production after winter maintenance. Earnings of $50m to $68m before interest, taxes, depreciation and amortisation (ebitda) are up on the previous $4.1m loss. A closing net debt balance of $300m was expected. Synlait expected its underlying net profit would break even for the full year. The company was expecting underlying ebitda of $100m to $110m compared with $45.2m previously. Synlait has yet to close its books for the financial year, and the preliminary update remained subject to the year-end wrap up, including an audit. It continues to comply with its banking covenants. Chief executive Richard Wyeth said in a statement that Synlait had strong foundations and its assets were well-located, with the capacity and capability to manufacture complex products in high demand around the world. "The company's recovery had been tracking in line with expectations and while turnaround will take time, I am confident of success," he said He joined Synlait 10 weeks ago.
National Business Review
5 days ago
- National Business Review
Aussie rate cut likely in August as inflation falls again
Australia 2 mins to read Aussie rate cut likely in August as inflation falls again The Australian dollar fell, along with bond yields, while the ASX moved higher on the announcement. The RBA said it expected Q2 inflation to be 'stronger than forecast' but the actual figure was lower than market estimates.
